Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs Humana Inc — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $25.49 (market cap $142.30B), while Humana Inc trades at $406 (market cap $48.84B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 2.9× Humana Inc's market cap, and Banco Bilbao Vizcaya Argentaria SA pays the higher dividend (4.2%). Which is the better fit depends on your goals.
| BBVA | HUM | |
|---|---|---|
Market Cap | $142.30B | $48.84B |
Sector | Financials | Health |
52-Week High | $26.14 | $409.42 |
52-Week Low | $14.73 | $163.67 |
Dividend Yield | 4.2% | 0.87% |
Enterprise Value | — | $57.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $25.39, down 1.17% on the day, with a bullish technical signal from moving averages and strong fundamental metrics including a 26.51% net income margin and 18.67% ROE. Recent earnings beat expectations in Q1 2026, and revenue has grown steadily from $28.2B in 2022 to $39.4B in 2025. Positive analyst sentiment is reflected in a 53.85% buy rating, though legal and regulatory risks from ongoing probes in Spain present headwinds.
The outlook for BBVA remains positive given robust profitability and analyst support, but investors should weigh the stock's attractive valuation against litigation risks and sector volatility. Upside potential exists if earnings continue to exceed forecasts, but legal developments could pressure the share price near-term.
Humana (HUM) trades at $406.00, up 3.51% with strong technical bullish signals and recent earnings beats. The stock shows robust revenue growth reaching $129.66 billion in 2025, though net margins have compressed to 0.82%. Analyst sentiment is mixed with 32% buy ratings but a consensus price target of $354.33 below current levels. Recent developments include Medicare Advantage margin targets and Illinois Medicaid contract wins.
The outlook remains cautious despite operational strengths. While CenterWell expansion and margin recovery plans offer upside, current valuation at 43x P/E appears stretched relative to earnings growth. Key risks include regulatory scrutiny, healthcare utilization costs, and ongoing insider trading investigations that could pressure shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
